Plaque psoriasis & psoriatic arthritis patient who are anti-TNFα inadequate responders or patient w/ concomitant moderate to severe plaque psoriasis 300 mg SC inj given in 2 doses w/ initial dosing at wk 0, 1, 2, 3 & 4, followed by mthly maintenance dosing.
Psoriatic arthritis, ankylosing spondylitis & nr-axSpA 150 mg SC inj w/ initial dosing at wk 0, 1, 2, 3 & 4, followed by mthly maintenance dosing.